Partner Content Partner Content Why Does Quant-Led KOL Identification Fail In Growth Markets... When it comes to KOL identification mapping, there is no shortage of quant data around KOL and HCP activity out there.
Partner Content Partner Content Pathway To Effective Stakeholder Mapping Before developing any stakeholder engagement plan, it is crucial to have a clear understanding of all the relevant individuals and groups your product or device could directly impact or interest in
Oncology Liver cancer diagnostic gets FDA breakthrough status, with P... Mursla Bio CEO and founder Pierre Arséne discusses the breakthrough designation from the FDA for their blood test to catch liver cancer early.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
